An Update on AXS-07 (upcoming migraine medication)

A new study has come out on AXS-07, a new abortive combination medication. With all the talk about injections, many patients will be glad to see a new “pill” coming down the pipeline!

You can find out more about AXS-07 here. In short, it’s a new formulation of meloxicam/rizatriptan. The latest news comes from the completion of a phase 3 trial.

The quick summary that’s promoting AXS-07 is that it has been shown to “prevent pain progression”. So what does that mean?

For many in the trial, AXS-07 did lead to “pain freedom” between 2 and 24 hours, a common measurement when it comes to pain medication. But these numbers, although significant, weren’t unusually high, although some patients did find they were pain-free as quickly as in 30 minutes.

So the even better news is that almost 3/4 of patients in the trial found that their migraine attack didn’t go beyond “mild” when they used AXS-07. The same percentage went back to “normal functioning” within 24 hours.

The other good news – no serious side effects, and very few experienced the most common side effects (such as dizziness, fatigue, or paresthesia (eg “pins and needles” feeling on the skin).

For more information, see:

• New Migraine Treatment Prevents Pain Progression
• Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine